The efficacy in preclinical trials of the systemic administration of lipoprotein-associated phospholipase A2 inhibitors in ameliorating BRB damage during DR [78] has emphasized the treatment with statins as a possible treatment for DR because of their association with dyslipidemia. The gene discussed is PLA2G7; the disease is metabolic syndrome.